KELLY MANTIA: Open Payments
NPI 1679258222 · CEDARHURST, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$727 in 29 payments from 14 companies in 2025. Trend: 2023 $118 · 2024 $863 · 2025 $727
Food & beverage: $727
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 1 | $124 |
| Lilly USA, LLC | 4 | $80 |
| Novo Nordisk Inc | 4 | $78 |
| Sumitomo Pharma America, Inc. | 3 | $70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $61 |
| Novartis Pharmaceuticals Corporation | 2 | $60 |
| ABBVIE INC. | 2 | $49 |
| Astellas Pharma US Inc | 2 | $42 |
| SANOFI-AVENTIS U.S. LLC | 1 | $37 |
| Currax Pharmaceuticals LLC | 2 | $35 |
Products named: DUPIXENT, JARDIANCE, GEMTESA, MOUNJARO, LEQVIO, Ozempic, Veozah, TZIELD.
Industry payments across NY — which companies pay providers there.
